Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
10.92
+0.27 (2.54%)
Sep 22, 2026, 4:00 PM EDT - Market closed
Kazia Therapeutics Employees
Kazia Therapeutics had 6 employees as of June 30, 2025. The number of employees decreased by 1 or -11.76% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-11.76%
Revenue / Employee
$211,072
Profits / Employee
-$2,534,761
Market Cap
149.64M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 6 | -1 | -11.76% |
| Jun 30, 2024 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 146 |
| Immunic | 100 |
| Caribou Biosciences | 97 |
| Tenaya Therapeutics | 70 |
| Neumora Therapeutics | 63 |
| Armata Pharmaceuticals | 61 |
| Korro Bio | 57 |
| Corbus Pharmaceuticals Holdings | 36 |
KZIA News
- 23 hours ago - Kazia Therapeutics licensee doses first patient in Phase 1b/2a paxalisib trial - TheFly
- 23 hours ago - Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders - PRNewsWire
- 13 days ago - Kazia Therapeutics announces first patient dosed in PNOC035 study - TheFly
- 13 days ago - Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer - PRNewsWire
- 21 days ago - Kazia Therapeutics price target raised to $40 from $34 at BTIG - TheFly
- 21 days ago - Kazia Therapeutics announces new preclinical, translational data on paxalisib - TheFly
- 21 days ago - Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy - PRNewsWire
- 21 days ago - Kazia Therapeutics expands paxalisib trial into HR+/HER2- breast cancer - TheFly